Clinical Trial Update: Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports a terminated Phase 1/2 study evaluating Zotiraciclib (TG02) in combination with dose-dense or metronomic temozolomide, fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Temodar (Temozolomide)
• Zotiraciclib (zotiraciclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Tumor, Astrocytoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-09-28